Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine

Vaccine

Volumn 29, Issue 20, 2011, Pages 3628-3632

  Tseng, Hung Fu ^a   Smith, Ning ^a   Sy, Lina S ^a   Jacobsen, Steven J ^a  

^a Southern California Kaiser Permanente ^*  (United States)

Author keywords

Adult vaccine; Herpes zoster vaccine; Pneumococcal polysaccharide vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ARTICLE; ELECTRONIC MEDICAL RECORD; FEMALE; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; VACCINATION;

AGED; ANTIBODIES, VIRAL; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; VACCINATION;

EID: 79955080964     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.018     Document Type: Article

References (13)

1. Levin M.J., Oxman M.N., Zhang J.H., Johnson G.R., Stanley H., Hayward A.R., et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008, 197(March (6)):825-835.
2. Levin M.J., Barber D., Goldblatt E., Jones M., LaFleur B., Chan C., et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55years of age and older: duration of booster effect. J Infect Dis 1998, 178(November (Suppl 1)):S109-S112.
3. Tseng H.F., Smith N., Harpaz R., Bialek S.R., Sy L.S., Jacobsen S.J. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011, 305(January (2)):160-166.
4. Zostavax. prescribing information [package insert]. 2009 [cited 2010 October, 23, 2010]; Available from: http://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi2.pdf.
5. Macintyre C.R., Egerton T., McCaughey M., Parrino J., Campbell B.V., Su S.C., et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≧ 60 years old. Hum Vaccin 2010, 6(11):18-26. Nov 1.
6. Oxman M.N. Zoster vaccine: current status and future prospects. Clin Infect Dis 2010, 51(July (2)):197-213.
7. Weinberg A., Zhang J.H., Oxman M.N., Johnson G.R., Hayward A.R., Caulfield M.J., et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009, 200(October (7)):1068-1077.
8. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352(June (22)):2271-2284.
9. Donahue J.G., Choo P.W., Manson J.E., Platt R. The incidence of herpes zoster. Arch Intern Med 1995, 155(August (15)):1605-1609.
10. Jumaan A., Yu O., Jackson L.A., Bohlke K., Galil K., Seward J.F. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005, 191:2002-2007.
11. Mullooly J.P., Riedlinger K., Chun C., Weinmann S., Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 2005, 133(2):245-253. Apr.
12. Yawn B.P., Saddier P., Wollan P.C., St.Sauver J.L., Kurland M.J., Sy L.S. A Population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007, 83:255.
13. Lu P.J., Euler G.L., Harpaz R. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med 2011, 40(February (2)):e1-e6.